Overview

Phase 1 PK Study to Assess Safety, PK, Tolerability of HM15912 in Subjects With Renal Impairment and Normal Renal Function

Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
An Open-label, Single-dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HM15912 in Subjects with Renal Impairment and Matched Control Subjects with Normal Renal Function
Phase:
Phase 1
Details
Lead Sponsor:
Hanmi Pharmaceutical Company Limited